Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
99results about How to "Few side-effects" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Sulfonamide derivatives
InactiveUS20100197655A1Good potencyLow affinityBiocideNervous disorderCombinatorial chemistryPerylene derivatives
Owner:PFIZER LTD +1
Method of preventing or treating benign gynaecological disorders
ActiveUS8071576B2Few side-effectsLow recurrence rateBiocideOrganic active ingredientsDiseaseGynecological disorders
The present invention relates to a method of preventing or treating benign estrogen sensitive gynecological disorders in a female mammal, wherein the method comprises the administration to said female mammal of a combination of progestogen and androgen in an amount that is therapeutically effective to prevent or reduce the symptoms of these disorders. The present method is particularly suitable for preventing or treating disorders selected from the group consisting of endrometriosis, adenomyosis, uterine fibroids, dysmenorrhoea, menorrhagia and metrorrhagia. Another aspect of the invention relates to a pharmaceutical kit comprising a plurality of oral dosage units which comprise a progestogen in an amount equivalent to 3-500 μg levonorgestrel and either 5 to 250 mg dehydroepiandrosterone or 1 to 50 mg testosterone undecanoate.
Owner:PANTARHEI BIOSCI
Low-concentration atropine solution for preventing myopia progression and preparing method thereof
A low-concentration atropine solution for preventing myopia progression contains an atropine concentration less than 0.1% (w / w). Preferably, the atropine concentration is 0.05% (w / w) in optimal situation. The low-concentration atropine solution in treatment causes less photophobia and systemic side-effects to patients and has excellent compliance to reduce damages from ultraviolet and hazard blue light and to avoid visual morbidities such as cataract and retinal macula lutea deterioration.
Owner:CHANG GUNG MEMORIAL HOSPITAL
Methods of administering anti-inflammatory cyclooxygenase-2 selective inhibitors
InactiveUS20070003646A1Good choiceBroader spectrum of therapeutic benefitBiocideAntipyreticSide effectCyclooxygenase
Owner:LIPOPROTEIN TECH
Cancer Treatment Using C-Type Natriuretic Peptides
InactiveUS20050209139A1Reduce in quantityComplete remission ratePeptide/protein ingredientsDepsipeptidesC-type natriuretic peptideCancer type
The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and / or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention.
Owner:UNIV OF SOUTH FLORIDA
Targeted Delivery System for Bioactive Agents
InactiveUS20070258986A1Sufficient timeLow toxicityAntibacterial agentsBiocideActive agentBiological body
In accordance with the present invention, compounds, compositions and methods are provided that allow for the administration of a bioactive agent to an organism, including a human or an animal. The present invention can be used to treat or prevent a disease and / or disorder with a bioactive agent, or can be used to safely vaccinate a human or animal against a bioactive agent. The invention can also be used as a method for the delivery of bioactive agents for the treatment or prevention of a disease and / or a disorder, particularly targeted delivery of bioactive agents through the administration of glycoconjugates containing a bioactive agent bound to a targeting compound through a modified saccharide residue.
Owner:US DEPT OF HEALTH & HUMAN SERVICES
Sulfonamide derivatives
InactiveUS8153814B2Good potencyLow affinityBiocideNervous disorderSulfanilamideCombinatorial chemistry
Owner:PFIZER LTD +1
Cancer treatment using C-type natriuretic peptides
InactiveUS7488713B2Reduce in quantityComplete remission ratePeptide/protein ingredientsDepsipeptidesC-type natriuretic peptideProstate cancer
Owner:UNIV OF SOUTH FLORIDA
Device for influencing cell-growth mechanisms in vessels of a human or animal body
InactiveUS6978173B2Low degree of complicationFew side-effectsStentsHeart defibrillatorsHuman bodyCell growth
A device for influencing cell-growth mechanisms in vessels, in particular blood vessels, of a human or animal body, wherein to influence the cell growth mechanisms there is provided an excitation device (5; 5″′) which is adapted to produce stimulation currents in a region to be treated of the vessel (3; 3″′), wherein the frequency and / or the modulation frequency of the stimulation currents is in the range of frequencies at which distribution of secondary messenger substances controlling cell growth in the cells of the vessel (3; 3″′) is influenced. Implant for influencing cell-growth mechanisms in such vessels.
Owner:BIOTRONIK MESS UND THERAPIEGERAETE GMBH & CO
Identification of signature genes associated with hepatocellular carcinoma
InactiveUS20110257035A1Lower levelImprove survivalPeptide librariesNucleotide librariesRegimenTumor Biomarkers
The present invention relates to, for example, (1) a novel method for identification of clinically useful serum and / or tumor biomarkers and expression signatures that can be used for detection, prognostication and guidance for the treatment of patients with hepatocellular carcinoma (HCC); and (2) discovery of an expression signature that can be used to monitor and / or study the efficacy of a chemotherapeutic regimen, such as, for example, sorafenib (solely or in combination with other agents). The present invention also provides a method for predicting clinical outcomes, such as, for example, overall survival (OS), time to progression (TTP) and / or likelihood of benefitting from a chemotherapeutic treatment (i.e., sorafenib) in HCC patients based on the analysis of such biomarkers.
Owner:BAYER HEALTHCARE LLC
Preventives/remedies for urinary disturbance
InactiveUS20070099986A1Function increaseLow urinary tract symptomBiocideOrganic compound preparationHydrogen atomHydroxy group
A compound represented by the formula: wherein Ar represents a group represented by the formula: (wherein Y represents methylene or an oxygen atom, R1 represents aminosulfonyl, C1-6 alkylaminosulfonyl, C1-6 alkylcarbonylamino or C1-6 alkylsulfonylamino, R2 represents a hydrogen atom or C1-6 alkyl, R3 represents C1-6 alkyl, and R4 represents a hydrogen atom or C1-6 alkyl); X represents a carbonyl group, or a methylene group which may be substituted with a hydroxy group; and L represents an optionally substituted C4-5 alkylene group, or a salt thereof is provided.
Owner:TAKEDA PHARMA CO LTD
Compositions Comprising Strontium and Vitamin D and Uses Thereof
InactiveUS20080026037A1Convenient treatmentFew side-effectsHeavy metal active ingredientsBiocideStrontium carbonateStrontium chloride
The invention relates to the finding that very favorable pharmacokinetic characters are obtained by combining two strontium salts in one pharmaceutical composition. The present invention relates in one aspect to a pharmaceutical composition comprising at least two strontium salts for use as a medicament, and in particular for the treatment and prevention of bone disorders such as osteoporosis. The composition preferably comprises strontium carbonate and strontium chlorides. Further included may be a vitamin D compound, preferably vitamin D3.
Owner:MOKWALO SPF SA
Heat shock protein inducer
InactiveUS6846845B2Small toxicityFew side-effectsBiocideKetone active ingredientsHeat shockReperfusion injury
A heat shock protein inducer is provided for purposes of preventing or treating ischemic disease or ischemia / reperfusion injury. This heat shock protein inducer has geranylgeranylacetone as an active ingredient and induces heat shock proteins in the heart.
Owner:TAKAHASHI NAOHIKO +3
Method of making antitussive medicine and relieving cough
InactiveUS20070060564A1Good treatment effectFew side-effectsBiocideAnimal repellantsMedicinal herbsChemical composition
Method for relieving cough using an effective antitussive chemical compound belonging to stemoamide or tuberostemospironine and method for manufacturing pharmaceutical compositions for treating or relieving cough in human and animal subjects which including a stemoamide or tuberostemospironine compound. In addition, the antitussive property of the compounds provides a method for assessing the quality of herbs traditionally used in treating cough by analyzing the content of the effective chemical ingredient, i.e., compounds of stemoamide type and / or tuterostemospironine type. It further provides a method for identifying medicinal herbs which may be used for relieving cough by phytochemical determination of the existence of compounds that are of stemoamide or tuterostemospironine type.
Owner:THE CHINESE UNIVERSITY OF HONG KONG
Agent for inhibiting production of hepatitis c virus and its use
InactiveUS20100055065A1Significant anti-HCV activityFew side-effectsOrganic chemistryAntiviralsHydrogenSide effect
This invention provides an agent for inhibiting production of hepatitis C virus with notable anti-HCV activity and without side-effects. The agent comprises a proanthocyanidin polymer composition illustrated in the following the general formula (1),wherein R1 is hydrogen or hydroxyl, R2 is hydroxyl, R3 is hydrogen when R1 is either hydrogen or hydroxyl, but R3 is possibly hydroxyl when R1 is either hydrogen or hydroxyl to the extent that both R1 and R3 being hydroxyl is at most 40 percents in the proanthocyanidin polymer compositionsaid units of flavan-3-ol being bonded each other in any one of three patterns as follows;(i) a bond between carbon at the position 4 and carbon at the position 8,(ii) a bond between carbon at the position 4 and carbon at the position 6,(iii) a bond between carbon at the position 4 and carbon at the position 8, and between carbon at the position 2 and oxygen at the position 7.
Owner:MIYAZAKI PREFECTURAL INDAL SUPPORT FOUND +3
Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
ActiveUS20070142459A1Growth inhibitionImprove efficacyOrganic active ingredientsBiocideAbnormal tissue growthSquamous Carcinomas
In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infections by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting a squamous cell carcinoma, and methods of inhibiting the replication of a virus, by administering artemisinin-related compounds.
Owner:GEORGETOWN UNIV
Pharmaceutical combinations of a CDK4/6 inhibitor and a B-RAF inhibitor
ActiveUS9700557B2Inhibit progressAvoid symptomsOrganic active ingredientsNervous disorderOncologyProliferative disease
A pharmaceutical combination comprising (a) CDK4 / 6 inhibitor (b) a B-Raf inhibitor, and optionally (c) a MEK 1 / 2 inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
Owner:ARRAY BIOPHARMA
Pharmaceutical Combinations
InactiveUS20160339023A1Reduce morbidityInhibit progressNervous disorderRespiratory disorderDiseaseReceptor
A pharmaceutical combination comprising (a) an ALK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one HDMA-2 / p53 receptor inhibitor or a pharmaceutically acceptable salt, or at least one BRaf inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of cancer; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
Owner:NOVARTIS AG
Fused polycyclic compounds
InactiveUS20060258637A1High medicinal valueFew side-effectsBiocideSenses disorderPolycyclic compoundDiabetes mellitus
The following fused polycyclic compound, analogues thereof or pharmaceutically acceptable salts thereof have an effect of increasing the sugar-transporting capacity and an effect of lowering the blood glucose level and, therefore, they are useful for preventing and / or treating diabetes and the like. wherein R is a methoxy group, Y is a (2-thiazolyl)-2-ethylcarbonyl group, R10 and R13 are hydrogen atoms, and R11 and R12 are methyl groups.
Owner:AJINOMOTO CO INC
Fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
InactiveUS20060194789A1High medicinal valueFew side-effectsBiocideSenses disorderPolycyclic compoundDiabetes mellitus
The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. wherein R represents an alkoxy group, R′ represents an oxazolylpropionyl group or a thiazolylpropionyl group, and R″ represent a hydrogen atom.
Owner:EA PHARMA CO LTD
Anti-pad2 antibodies and treatment of autoimmune diseases
InactiveUS20150376294A1Few side-effectsPatient compliance is goodAntibody ingredientsImmunological disordersExtracellularDisease
The present invention relates to anti-peptidylarginine deiminase 2 (PAD2) antibodies and anti-PAD2 antibodies for use in the treatment of autoimmune diseases characterized by extracellular citrullination, such as rheumatoid arthritis (RA). The invention further relates to a method for treatment of an autoimmune disease characterized by extracellular citrullination comprising the administration of a suitable amount of an anti-PAD2 antibody to a subject.
Owner:RIGSHOSPITALET
Synergistic regulated cell death induction with hsp90 inhibitors and nanosecond pulsed electric fields
InactiveUS20180110978A1Efficient killingEliminate side effectsOrganic active ingredientsElectrotherapySide effectCancer cell
Methods for treating tumors employing HSp90 inhibitors in combination with nanosecond pulsed electric fields (nsPEFs) are disclosed. The methods are directed to induce regulated cell death (RCD) in tumor cells and tissues. Further, Hsp90 inhibitors in combination with nsPEF are used at low non-toxic concentrations, thereby reducing the side-effects associated with these drugs. Additionally, nsPEFs are employed at lower electric fields and / or with fewer number of pulses than when nsPEFs are employed alone. Further, the mechanisms by which nsPEFs and Hsp90 inhibitors act upon cancer cells are different, thereby combining these treatments results in a synergistic effect.
Owner:OLD DOMINION UNIVERSITY RESEARCH FOUNDATION
Non-invasive device for lowering intraocular pressure
InactiveUS20110087138A1Lower eye pressureFew side-effectsEye surgeryVibration massageNon invasiveOcular surface
The present invention provides devices and methods for non-invasively lowering intraocular pressure. In particular, some non-invasive intraocular pressure lowering devices of the invention comprise an oscillating element having a proximal end and a terminal probe. Typically, the terminal probe of said oscillating element comprises a substantially non-abrasive material that is adapted to be in contact with an ocular surface without causing any significant damage to the tissue and is shaped to conform to ocular surface at the limbal region. Devices also include an oscillating mechanism that is operatively connected to the proximal end of said oscillating tip such that when oscillating mechanism is in operation said oscillating tip moves axially without damaging ocular cells. Intraocular pressure lowering devices of the present invention are capable of non-invasively transmitting mechanical force to the tissue proximate to the limbal tissue.
Owner:UNIV OF COLORADO THE REGENTS OF
Powder for treating mumps
The invention belongs to the field of Chinese medicinal preparations, in particular to the field of powder. The externally used powder for treating mumps comprises the following Chinese medicinal materials: rhubarb, rhizoma arisaematis cum bile, rehmanniae praeparatum, oyster shell, medcinal evodia fruit and figwortflowerpicrorhizarhizome of which the weight ratio is 10-30:5-25:1-35:5-25:5-15:5-15. The medcinal evodia fruit, the oyster shell and the figwortflowerpicrorhizarhizome are ground repeatedly into fine powder; the rhizoma arisaematis cum bile, the rhubarb and the rehmanniae praeparatum are crushed together; and then all the medicaments are mixed together and packaged by a unit dosage of between 90 and 100 grams. When the externally used powder is used, a proper amount of rice vinegar is added into the powder and the mixture is mixed evenly. The powder for treating the mumps is convenient in use, has no toxic or side effect, suits the remedy to the case, and improves the treatment effect.
Owner:TIANJIN ZHONGBAO PHARMACY
Cartilage/bone inducing materials for reparation
InactiveUS6903071B2High bio-absorptionHigh affinityPeptide/protein ingredientsSkeletal disorderEthylene oxideAqueous solution
A cartrilage and bone morphogenetic repairing composition comprising a collagen-free aqueous solution of a polyoxyethylene-polyoxypropylene and an effective amount of a bone morphogenetic protein, the molecular weight of polyoxypropylene as a constituent of said polyoxyethylene-polyoxypropylene molecular is 900 to 4,000 in a unit of Dalton (D) and the ethylene oxide content is 5 to 90% by weight of the polyoxyethylene-propoxypropylene molecule whereby the solution is liquid at 1 to 30° C. and gelatinizes at about 37° C. and a method of using the same.
Owner:BIOPHARM GES ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA
Dopamine d2 receptor ligands
ActiveUS20180155283A1More selectivityMore functionalityNervous disorderReceptors for neuromediatorsDopamine receptor D1Functional selectivity
The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopammode inergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0-arrestin pathway and / or on the cAMP pathway.
Owner:THE BROAD INST INC +1
Composition for use in treating and preventing inflammation related disorder
ActiveUS20140141077A1Few side-effectsLow doseBiocideOrganic active ingredientsPulmonary diseaseProctitis
The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (HA) or HA mixture, whereas the HA or the HA mixture as a delivery vehicle can be a formulation including at least two HAs having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (GERD), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (IBD), Crohn's Disease, irritable bowel syndrome (IBS), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis.
Owner:AIHOL CORP
Pharmaceutical Combinations Comprising a B-RAF Inhibitor, and EGFR Inhibitor and Optionally a PI3K-Alpha Inhibitor
ActiveUS20150265616A1Few side-effectsReliable responseBiocideOrganic active ingredientsDiseasePharmaceutical drug
A pharmaceutical combination comprising (a) a B-Raf inhibitor, (b) a EGFR inhibitor and, optionally, (c) a PI3K inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
Owner:ARRAY BIOPHARMA
Cartilage/bone inducing materials for preparation
InactiveUS20050013864A1High bio-absorptionHigh affinityPowder deliveryOrganic active ingredientsTreatment effectPolyoxypropylenediol
A cartilage and bone morphogenic repairing material which contains a bone morphogenic protein and a polyoxyethylene-polyoxypropylene glycol. In particular, it is preferable that a molecular weight of a polyoxypropylene, i.e., a component of said polyoxyethylene-polyoxypropylene glycol, is in the range of about 1,500-4,000 and a weight ratio of ethylene oxide is in the range of 40-80% / molecule, and a concentration of said polyoxyethylene-polyoxypropylene glycol in an aqueous solution is about 10-50%. It may be applied in a cartilage and bone morphogenic method requiring no surgical operation and which comprises a bone morphogenic protein and a carrier having a high bio-absorption, a good affinity to the bone morphogenic protein and capable of temperature dependent gel-sol reversible transition. It is convenient to apply locally to the site of a bone fracture or bone defect with an efficient treatment effect.
Owner:BIOPHARM GES ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA
Chinese medicinal composition for treating hepatitis and preparation method thereof
InactiveCN102671056ASymptoms improvedImprove liver functionDigestive systemAntiviralsSide effectOyster
The invention relates to the technical field of Chinese medicines, and in particular discloses a Chinese medicinal composition for treating hepatitis and a preparation method thereof. The Chinese medicinal composition for treating hepatitis is prepared from the following Chinese herbal medicines in part by weight: 100 to 140 parts of red paeony root, 50 to 70 parts of corydalis tuber, 50 to 70 parts of tuckahoe, 50 to 70 parts of Chinese thorowax root, 50 to 70 parts of oyster, 50 to 70 parts of dried orange peel, 50 to 70 parts of scorched fructus crataegi, 100 to 140 parts of red-rooted salvia root, 50 to 70 parts of large-head atractylodes rhizome, 50 to 70 parts of umbellate pore fungus, 50 to 70 parts of bitter orange, 50 to 70 parts of tree peony bark and 50 to 70 parts of scorched malt. The Chinese medicinal composition for treating hepatitis is reasonable in formula and reliable in curative effect, can be used for effectively treating chronic hepatitis and liver cirrhosis, and has the advantages of obvious therapeutic effect and small side effect.
Owner:江苏平光信谊(焦作)中药有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com